검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 72 trials | Cytochrome P450 (CYP, Cytochrome P450, Cytochrome P450 (CYP) Cocktail) Amgen·Metastatic Castration-resistant Pr… ORR null |
|---|---|---|
Overview Program | androgen deprivation therapy (ADT) | Cytochrome P450 (CYP) Cocktail |
Overview Company | Istituto Clinico Humanitas | Amgen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Oligorecurrent and Oligoprogressive Pros | Metastatic Castration-resistant Prostate |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients | Metastatic Castration-resistant Prostate Cancer; Prostate Cancer |
Overview Phase | PRECLINICAL | PHASE_1 |
Overview Status | RECRUITING | DISCONTINUED |
MoA Mechanism | targeting Vβ6 and Vβ10 T-cell receptor | inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway |
MoA Biomarker | biomarker-driven studies in larger cohorts to refine treatment strategies | biomarker in OSCC management |
PK/PD Species | Mouse | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse |
PK/PD Experiment | pd | Pharmacokinetic |
Toxicology Species | Mouse | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro | Mouse |
Toxicology Major finding | SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.. The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate an… | hepatotoxicity, QT interval alterations, neuropsychiatric effects, and cytochrome P450-medi |
Clinical PFS | 0 | — |
Clinical Result source | ClinicalTrials.gov NCT01531205 | ClinicalTrials.gov NCT00779259 |
Clinical Data Tier / Score | S · 29 | C · 9 |
Clinical Program phase | PRECLINICAL | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 72 trials | Cytochrome P450 (CYP, Cytochrome P450, Cytochrome P450 (CYP) Cocktail) Amgen·Metastatic Castration-resistant Pr… ORR null |
|---|---|---|
Overview Program | androgen deprivation therapy (ADT) | Cytochrome P450 (CYP) Cocktail |
Overview Company | Istituto Clinico Humanitas | Amgen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Oligorecurrent and Oligoprogressive Pros | Metastatic Castration-resistant Prostate |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients | Metastatic Castration-resistant Prostate Cancer; Prostate Cancer |
Overview Phase | PRECLINICAL | PHASE_1 |
Overview Status | RECRUITING | DISCONTINUED |
MoA Mechanism | targeting Vβ6 and Vβ10 T-cell receptor | inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway |
MoA Biomarker | biomarker-driven studies in larger cohorts to refine treatment strategies | biomarker in OSCC management |
PK/PD Species | Mouse | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse |
PK/PD Experiment | pd | Pharmacokinetic |
Toxicology Species | Mouse | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro | Mouse |
Toxicology Major finding | SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.. The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate an… | hepatotoxicity, QT interval alterations, neuropsychiatric effects, and cytochrome P450-medi |
Clinical PFS | 0 | — |
Clinical Result source | ClinicalTrials.gov NCT01531205 | ClinicalTrials.gov NCT00779259 |
Clinical Data Tier / Score | S · 29 | C · 9 |
Clinical Program phase | PRECLINICAL | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교